Better Cannabis Buy in 2020: Aurora Cannabis (TSX:ACB) Vs. Tilray (NASDAQ:TLRY)

Aurora Cannabis and Tilray are two giants in the cannabis space. Will they make a comeback in 2020?

| More on:
Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

While cannabis stocks were decimated in 2019, they have regained some lost ground this month. Investors and analysts were buoyed by strong quarterly results of OrganiGram, which drove several stocks higher last week. However, it remains to be seen if pot companies can continue to beat analyst estimates in their upcoming results.

A lot of marijuana producers will benefit from a strong demand for Cannabis 2.0 products. There is also the possibility of several retail stores opening in Canada’s Ontario province, which will drive up demand for pot products.

It is almost impossible to time the market, and the staggering decline witnessed in the cannabis space last year provides as good an opportunity, if any, to buy marijuana stocks.

Aurora Cannabis is valued at $2.9 billion

Shares of Canada’s marijuana heavyweight Aurora Cannabis (TSX:ACB)(NYSE:ACB) have a market cap of $2.9 billion. It has debt of $800 million and a cash balance of $192 million, which means Aurora’s enterprise value stands at $3.49 billion.

Analysts expect Aurora’s sales to rise by 53.9% to $381.64 million in fiscal 2020 and by 74.5% to $666 million in fiscal 2021. This means the stock is trading at a market cap-to-forward sales ratio of eight, which seems a reasonable multiple for a growth stock. Aurora’s price-to-book ratio of 0.60 also makes it an attractive pick for value investors.

In the last 12 months, Aurora stock has fallen 67% and is currently trading at $2.60, which is 81% below its 52-week high.

Tilray (NASDAQ:TLRY) have a market cap of US$2.1 billion. It has a debt of $437 million and a cash balance of $167 million, which means Tilray’s enterprise value stands at $2.4 billion.

Analysts expect Tilray’s sales to rise by 306.3% to US$175.23 million in 2019 and by 76.4% to US$309.3 million in 2020. This means the stock is trading at a market cap-to-forward sales ratio of 12. Tilray’s price-to-book ratio stands at 5.06, while the price-to-sales ratio is currently 16.5.

We can see that Tilray shares are trading at a higher multiple compared to Aurora Cannabis. But Tilray is also growing sales at a higher rate and is bound to trade at a premium.

In the last 12 months, Tilray stock has fallen 71% and is currently trading at US$21.1, which is 77% below its 52-week high. Tilray stock went public at $17 per share in July 2018. It then reached a record high of $300 in intra-day trading in September that year before losing considerable market value. Now the stock is trading 20% above its IPO price.

Will marijuana stocks rise in 2020?

In case pot stocks stage a recovery this ever, investors can place their bets on these two cannabis giants. In 2017, Aurora stock gained an impressive 400% and drove several other pot stocks higher that year.

As mentioned earlier, a lot will depend on the earnings of large marijuana companies. In case they manage to beat Wall Street estimates and provide strong guidance, the stocks will begin their upward spiral.

A strong guidance will also mean an increase in overall demand, which will result in lower inventory levels and an increase in profit margins. Aurora stock has been flat, while Tilray is up 30% in 2020. Will they crush market returns or fall to historic lows in 2020?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends OrganiGram Holdings and OrganiGram Holdings. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »